247 related articles for article (PubMed ID: 20065949)
1. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
Chou JL; Su HY; Chen LY; Liao YP; Hartman-Frey C; Lai YH; Yang HW; Deatherage DE; Kuo CT; Huang YW; Yan PS; Hsiao SH; Tai CK; Lin HJ; Davuluri RV; Chao TK; Nephew KP; Huang TH; Lai HC; Chan MW
Lab Invest; 2010 Mar; 90(3):414-25. PubMed ID: 20065949
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation and decreased expression of the TGF-β/Smad target gene FBXO32 in esophageal squamous cell carcinoma.
Guo W; Zhang M; Shen S; Guo Y; Kuang G; Yang Z; Dong Z
Cancer; 2014 Aug; 120(16):2412-23. PubMed ID: 24798237
[TBL] [Abstract][Full Text] [Related]
3. Preliminary Study of the Role F-Box Protein 32 (FBXO32) in Colorectal Neoplasms Through the Transforming Growth Factor beta (TGF-β)/Smad4 Signalling Pathway.
Yuan X; Zhang Z; Jiang K; Wang X; Li Y
Med Sci Monit; 2018 Feb; 24():1080-1088. PubMed ID: 29465067
[TBL] [Abstract][Full Text] [Related]
4. Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.
Yeh KT; Chen TH; Yang HW; Chou JL; Chen LY; Yeh CM; Chen YH; Lin RI; Su HY; Chen GC; Deatherage DE; Huang YW; Yan PS; Lin HJ; Nephew KP; Huang TH; Lai HC; Chan MW
Epigenetics; 2011 Jun; 6(6):727-39. PubMed ID: 21540640
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer.
Zhang YW; Zheng Y; Wang JZ; Lu XX; Wang Z; Chen LB; Guan XX; Tong JD
Epigenetics; 2014 Jun; 9(6):896-909. PubMed ID: 24699858
[TBL] [Abstract][Full Text] [Related]
6. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
7. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.
Sakuma M; Akahira J; Ito K; Niikura H; Moriya T; Okamura K; Sasano H; Yaegashi N
Cancer Sci; 2007 Mar; 98(3):380-6. PubMed ID: 17270028
[TBL] [Abstract][Full Text] [Related]
9. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
10. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma.
Tong JH; Ng DC; Chau SL; So KK; Leung PP; Lee TL; Lung RW; Chan MW; Chan AW; Lo KW; To KF
BMC Cancer; 2010 Jun; 10():253. PubMed ID: 20525238
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
12. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.
Chan MW; Huang YW; Hartman-Frey C; Kuo CT; Deatherage D; Qin H; Cheng AS; Yan PS; Davuluri RV; Huang TH; Nephew KP; Lin HJ
Neoplasia; 2008 Sep; 10(9):908-19. PubMed ID: 18714391
[TBL] [Abstract][Full Text] [Related]
13. DNMT1-mediated regulating on FBXO32 promotes the progression of glioma cells through the regulation of SKP1 activity.
Quan J; Ma C
Environ Toxicol; 2024 Feb; 39(2):783-793. PubMed ID: 37782699
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.
Cai Y; An B; Yao D; Zhou H; Zhu J
Bioengineered; 2021 Dec; 12(2):10713-10722. PubMed ID: 34747309
[TBL] [Abstract][Full Text] [Related]
15. Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer.
Meng F; Sun G; Zhong M; Yu Y; Brewer MA
Br J Cancer; 2013 Feb; 108(3):579-86. PubMed ID: 23370212
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
17. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
Tang X; Yin X; Xiang T; Li H; Li F; Chen L; Ren G
Cancer Biomark; 2012-2013; 12(1):11-9. PubMed ID: 23321465
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Liao X; Li Z; Zheng H; Qian W; Zhang S; Chen S; Li X; Tang M; Xu Y; Yu R; Li M; Song L; Li J
Mol Cancer Res; 2023 Jul; 21(7):648-663. PubMed ID: 36961398
[TBL] [Abstract][Full Text] [Related]
20. Elucidating the mechanism of regulation of transforming growth factor β Type II receptor expression in human lung cancer cell lines.
Halder SK; Cho YJ; Datta A; Anumanthan G; Ham AJ; Carbone DP; Datta PK
Neoplasia; 2011 Oct; 13(10):912-22. PubMed ID: 22028617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
